Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
The global Neulasta (Pegfilgrastim) and Biosimilar market was valued at US$ 2501.4 million in 2022 and is projected to reach US$ 3816.3 million by 2029, at a CAGR of 6.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Brand Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neulasta (Pegfilgrastim) and Biosimilar include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
This report aims to provide a comprehensive presentation of the global market for Neulasta (Pegfilgrastim) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neulasta (Pegfilgrastim) and Biosimilar. This report contains market size and forecasts of Neulasta (Pegfilgrastim) and Biosimilar in global, including the following market information:
Global Neulasta (Pegfilgrastim) and Biosimilar Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Neulasta (Pegfilgrastim) and Biosimilar Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Neulasta (Pegfilgrastim) and Biosimilar companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neulasta (Pegfilgrastim) and Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neulasta (Pegfilgrastim) and Biosimilar Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar Market Segment Percentages, by Type, 2022 (%)
Brand
Biosimilar
Global Neulasta (Pegfilgrastim) and Biosimilar Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacy
Other
Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neulasta (Pegfilgrastim) and Biosimilar revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neulasta (Pegfilgrastim) and Biosimilar revenues share in global market, 2022 (%)
Key companies Neulasta (Pegfilgrastim) and Biosimilar sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Neulasta (Pegfilgrastim) and Biosimilar sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neulasta (Pegfilgrastim) and Biosimilar, market overview.
Chapter 2: Global Neulasta (Pegfilgrastim) and Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Neulasta (Pegfilgrastim) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neulasta (Pegfilgrastim) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neulasta (Pegfilgrastim) and Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Neulasta (Pegfilgrastim) and Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neulasta (Pegfilgrastim) and Biosimilar Overall Market Size
2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size: 2022 VS 2029
2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Neulasta (Pegfilgrastim) and Biosimilar Players in Global Market
3.2 Top Global Neulasta (Pegfilgrastim) and Biosimilar Companies Ranked by Revenue
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Companies
3.4 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Companies
3.5 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neulasta (Pegfilgrastim) and Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neulasta (Pegfilgrastim) and Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Neulasta (Pegfilgrastim) and Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Neulasta (Pegfilgrastim) and Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Brand
4.1.3 Biosimilar
4.2 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Sales & Forecasts
4.3.1 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Neulasta (Pegfilgrastim) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Other
5.2 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Sales & Forecasts
5.3.1 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Neulasta (Pegfilgrastim) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Sales & Forecasts
6.3.1 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2029
6.4.3 US Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.4.4 Canada Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.4.5 Mexico Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2029
6.5.3 Germany Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.4 France Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.5 U.K. Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.6 Italy Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.7 Russia Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.5.9 Benelux Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2029
6.6.3 China Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.6.4 Japan Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.6.5 South Korea Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.6.7 India Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2029
6.7.3 Brazil Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.7.4 Argentina Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales, 2018-2029
6.8.3 Turkey Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.8.4 Israel Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
6.8.6 UAE Neulasta (Pegfilgrastim) and Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Viatris
7.2.1 Viatris Company Summary
7.2.2 Viatris Business Overview
7.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.2.5 Viatris Key News & Latest Developments
7.3 Coherus
7.3.1 Coherus Company Summary
7.3.2 Coherus Business Overview
7.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.3.5 Coherus Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.4.5 Novartis Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Amneal Pharmaceutical
7.6.1 Amneal Pharmaceutical Company Summary
7.6.2 Amneal Pharmaceutical Business Overview
7.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.6.5 Amneal Pharmaceutical Key News & Latest Developments
7.7 Fresenius Kabi
7.7.1 Fresenius Kabi Company Summary
7.7.2 Fresenius Kabi Business Overview
7.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Major Product Offerings
7.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales and Revenue in Global (2018-2023)
7.7.5 Fresenius Kabi Key News & Latest Developments
8 Global Neulasta (Pegfilgrastim) and Biosimilar Production Capacity, Analysis
8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Production Capacity, 2018-2029
8.2 Neulasta (Pegfilgrastim) and Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Neulasta (Pegfilgrastim) and Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neulasta (Pegfilgrastim) and Biosimilar Supply Chain Analysis
10.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Value Chain
10.2 Neulasta (Pegfilgrastim) and Biosimilar Upstream Market
10.3 Neulasta (Pegfilgrastim) and Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
